Kusatsu/Shiga, Japan — September 27, 2017 — Takara Bio Inc. (Takara Bio), today announced that the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on September 26, 2017.


This clinical trial will be conducted in patients with unresectable advanced pancreatic cancer to evaluate safety of HF10 in combination with existing chemotherapeutic drug.
In this clinical trial, the HF10 manufactured at Center for Gene and Cell Therapy, Takara Bio’s facility, will be used.


Regarding domestic development and sales of oncolytic virus HF10, Takara Bio has an exclusive licensing agreement with Otsuka Pharmaceutical Co., Ltd., and both companies will consult with each other and aim for the early approval of HF10 in Japan.


“Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan” —Our news release June 1, 2017